The Exploratory Clinical Trials on the Primary Safety and Effectiveness of High Myopic Posterior Scleral Fixation System
High Myopic Posterior Scleral Fixation System
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Qianying Gao, MD,Ph.D
- Phone Number: 020-28687088
- Email: kevin.gao@vesber.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510030
- Recruiting
- The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18~65, male or female;
- Refractive ranges from -6.00d to -25.00d;
- The axial length of the operative eye was 26-32mm;
- Macular cleavage 200-1000μm;
- Corrected visual acuity of the operative eye < 0.3;
- Able to understand the purpose of the test, voluntarily participate and sign the informed consent form.
Exclusion Criteria:
- Known allergy to silica gel and patients with scar constitution;
- Ocular inflammation;
- Fundus hemorrhage;
- Macular hole;
- Macular cleavage of the contralateral eye greater than 200μm;
- Corrected visual acuity of contralateral eye < 0.4;
- Opacity of the refractive medium;
- Eye tumor;
- History of hyperthyroidism;
- Other ophthalmic concomitant diseases that cannot be controlled, such as diabetic retinopathy, hypertensive fundus lesions, optic nerve atrophy, etc.;
- Severe impairment of liver and kidney function and/or severe systemic diseases (such as cardiovascular, respiratory, digestive, nervous, endocrine, genitourinary, etc., depending on the tolerance of surgery);
- Women who are pregnant (determined by a blood pregnancy test at the first visit), who are preparing for pregnancy during the test, and who are breastfeeding;
- a history of drug abuse or alcohol abuse;
- participate in other drug or medical device clinical trials within 30 days prior to the screening of this clinical trial;
- Any condition of the subject that the study physician considers to be an impediment to the clinical trial (e.g. subject's susceptibility to mental stress, uncontrollable mood, depression, etc.);
- Poor compliance of the subject, unable to complete the test process as required.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: HM experimental group
Intraocular implant test product
|
Implant HM into the eye through posterior scleral reinforcement
Other Names:
|
|
No Intervention: Natural observation control group
Natural observation of the disease changes, no surgical intervention
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Macular reduction rate
Time Frame: 24 weeks
|
24 weeks after implantation of the High Myopic Posterior Scleral Fixation System
|
24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Best corrected visual acuity
Time Frame: Baseline (Before surgery), 1 day, 1 week, 4 weeks, 12 weeks, 24 weeks,
|
ETDRS table
|
Baseline (Before surgery), 1 day, 1 week, 4 weeks, 12 weeks, 24 weeks,
|
|
Axial length
Time Frame: Baseline (Before surgery), 24 weeks after surgery
|
A-scan
|
Baseline (Before surgery), 24 weeks after surgery
|
|
Diopter
Time Frame: Baseline (Before surgery), 24 weeks after surgery
|
Refractometer
|
Baseline (Before surgery), 24 weeks after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Wenbing Wei, MD,Ph.D, Beijing Tongren Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TREC2019-30.A2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.